Published in J Immunol on September 01, 1974
Dendritic cells are critical accessory cells for thymus-dependent antibody responses in mouse and in man. Proc Natl Acad Sci U S A (1983) 3.25
The modulation of lymphocyte functions by molecules secreted by macrophages. I. Description and partial biochemical analysis. J Exp Med (1975) 2.54
Secretory function of mononuclear phagocytes: a review. Am J Pathol (1976) 2.12
Differential stimulation of murine lymphoma growth in vitro by normal and BCG-activated macrophages. J Exp Med (1975) 1.77
Role of interleukin 1 in anti-immunoglobulin-induced B cell proliferation. J Exp Med (1983) 1.69
Regulation of B-lymphocyte clonal proliferation by stimulatory and inhibitory macrophage-derived factors. J Exp Med (1977) 1.67
Proliferation and differentiation of single hapten-specific B lymphocytes is promoted by T-cell factor(s) distinct from T-cell growth factor. Proc Natl Acad Sci U S A (1982) 1.53
The modulation of lymphocyte functions by molecules secreted by macrophages. II. Conditions leading to increased secretion. J Exp Med (1976) 1.30
The macrophage as a secretory cell in chronic inflammation. Agents Actions (1976) 1.18
Prostaglandin E inhibition of T-lymphocyte colony formation: a possible mechanism of monocyte modulation of clonal expansion. J Clin Invest (1979) 1.18
Regulation of Fc fragment-induced murine spleen cell proliferation. J Exp Med (1980) 1.12
B-cell activation by lipopolysaccharide. Distinct pathways for induction of mitosis and antibody production. J Exp Med (1977) 1.11
Regulation of immunity and inflammation by mediators from macrophages. Am J Pathol (1976) 1.03
Enhanced immunogenicity of a sequence derived from hepatitis B virus surface antigen in a composite peptide that includes the immunostimulatory region from human interleukin 1. Proc Natl Acad Sci U S A (1990) 0.88
Enhancement of in vitro immunoglobulin synthesis of human lymphocytes by lysosomal enzymes from polymorphonuclear leucocytes. Clin Exp Immunol (1977) 0.81
The establishment of continuous macrophage cell lines from peripheal blood monocytes. Immunology (1980) 0.80
Mechanisms of action of 'lymphocyte activating factor' (LAF) I. Association of lymphocyte activating factor action with early DNA synthesis in PHA-stimulated lymphocytes. Immunology (1977) 0.80
Accessory cell function in immune responses in vivo: enhancing effect of radioresistant spleen cells on antibody response to SRBC in rats. Immunology (1980) 0.75
An interleukin 1 like factor stimulates bone resorption in vitro. Nature (1984) 3.71
Isolation of an interleukin-1-like factor from human joint effusions. Arthritis Rheum (1983) 2.75
Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc Natl Acad Sci U S A (1991) 2.67
Stimulation by human interleukin 1 of cartilage breakdown and production of collagenase and proteoglycanase by human chondrocytes but not by human osteoblasts in vitro. Biochim Biophys Acta (1984) 2.00
The four biochemically distinct species of human interleukin 1 all exhibit similar biologic activities. J Immunol (1985) 1.78
Myelin in multiple sclerosis is developmentally immature. J Clin Invest (1994) 1.52
Immune responses in vitro. X. Functions of macrophages. J Immunol (1974) 1.47
Ribosomal RNA and ribosomes from mitochondria of Neurospora crassa. Proc Natl Acad Sci U S A (1967) 1.40
The adjuvanticity of interleukin 1 in vivo. J Immunol (1983) 1.35
Peptidylarginine deiminase: a candidate factor in demyelinating disease. J Neurochem (2002) 1.31
Stimulation of the proliferation of human bone cells in vitro by human monocyte products with interleukin-1 activity. J Clin Invest (1985) 1.30
Release of interleukin-1 from human synovial tissue in vitro. Arthritis Rheum (1985) 1.25
Hybridization of mitochondrial ribosomal RNA. J Mol Biol (1969) 1.23
Antihypertensive activity of N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-Ala-L-Pro (MK-421), an orally active converting enzyme inhibitor. J Pharmacol Exp Ther (1981) 1.22
Transglutaminase inhibition by 2-[(2-oxopropyl)thio]imidazolium derivatives: mechanism of factor XIIIa inactivation. Biochemistry (1994) 1.22
Attenuation of hydrochlorothiazide-induced hypokalemia in dogs by a beta-adrenergic blocking drug, timolol. Eur J Pharmacol (1975) 1.20
Multiple sclerosis: an important role for post-translational modifications of myelin basic protein in pathogenesis. Mol Cell Proteomics (2003) 1.19
In vitro activation of human chondrocytes and synoviocytes by a human interleukin-1-like factor. Arthritis Rheum (1984) 1.17
Purification and properties of human B cell-activating factor. J Immunol (1979) 1.17
Interleukin 1 enhances synovial cell hyaluronate synthesis. Proc Soc Exp Biol Med (1984) 1.14
Non-peptide GPIIb/IIIa inhibitors. 20. Centrally constrained thienothiophene alpha-sulfonamides are potent, long acting in vivo inhibitors of platelet aggregation. J Med Chem (1999) 1.09
Reduction of serum Interleukin-1-like activity after treatment with dexamethasone. J Leukoc Biol (1985) 1.09
The effects of monocyte-conditioned medium and interleukin 1 on the synthesis of collagenous and non-collagenous proteins by mouse bone and human bone cells in vitro. Biochim Biophys Acta (1984) 1.01
Hydrophobic and electrostatic interactions of myelin basic proteins with lipid. Participation of N-terminal and C-terminal portions. Biochemistry (1981) 1.00
Stimulation of the release of a B cell-activating factor from human monocytes. Cell Immunol (1976) 1.00
Isolation of a highly purified myelin protein. Biochemistry (1971) 0.98
The effect of basic myelin protein on multilayer membrane formation. Biophys J (1981) 0.95
Characterization of a recombinant murine 18.5-kDa myelin basic protein. Protein Expr Purif (2000) 0.94
Genetic influences on the adjuvanticity of muramyl dipeptide in vivo. J Immunol (1982) 0.93
Resolution of a factor that enhances the antibody response of T cell-depleted murine splenocytes from several other monocyte products. Cell Immunol (1976) 0.92
The role of charge microheterogeneity of basic protein in the formation and maintenance of the multilayered structure of myelin: a possible role in multiple sclerosis. J Neurosci Res (1986) 0.92
Paclitaxel (Taxol) attenuates clinical disease in a spontaneously demyelinating transgenic mouse and induces remyelination. Mult Scler (2002) 0.90
Biochemical heterogeneity of human interleukin-1. Lymphokine Res (1985) 0.90
The relationship between bacterial endotoxin and human B cell-activating factor. J Immunol (1978) 0.89
The estimation of gastrin activity in blood. J Physiol (1968) 0.89
Highly deiminated isoform of myelin basic protein from multiple sclerosis brain causes fragmentation of lipid vesicles. J Neurosci Res (1999) 0.88
T cells of multiple sclerosis patients target a common environmental peptide that causes encephalitis in mice. J Immunol (2001) 0.87
Mechanism of action of human B cell-activating factor. I. Comparison of the plaque-stimulating activity with thymocyte-stimulating activity. J Immunol (1979) 0.87
Cryoelectron microscopy of protein-lipid complexes of human myelin basic protein charge isomers differing in degree of citrullination. J Struct Biol (2000) 0.87
Lipid phase separation induced by a hydrophobic protein in phosphatidylserine--phosphatidylcholine vesicles. Biochemistry (1977) 0.86
Nonspecific "lymphocyte activating" factors produced by macrophages. J Immunol (1979) 0.85
Is the myelin membrane abnormal in multiple sclerosis? J Membr Biol (1984) 0.84
Localization of the basic protein and lipophilin in the myelin membrane with a non-penetrating reagent. Biochim Biophys Acta (1977) 0.83
Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets. J Pharmacol Exp Ther (1998) 0.83
The N terminus of human myelin basic protein consists of C2, C4, C6, and C8 alkyl carboxylic acids. J Biol Chem (1992) 0.82
Synergy between paclitaxel plus an exogenous methyl donor in the suppression of murine demyelinating diseases. Mult Scler (2007) 0.82
The role of charge microheterogeneity of human myelin basic protein in the formation of phosphatidylglycerol multilayers. Biochem Biophys Res Commun (1985) 0.81
Conformational flexibility of a myelin protein. Biochemistry (1973) 0.81
3-Hydroxy-alpha-methyltyrosine progenitors: synthesis and evaluation of some (2-oxo-1,3-dioxol-4-yl)methyl esters. J Med Chem (1984) 0.80
Human proteolipid protein (PLP) mediates winding and adhesion of phospholipid membranes but prevents their fusion. Biochim Biophys Acta (1998) 0.80
The effects of deimination of myelin basic protein on structures formed by its interaction with phosphoinositide-containing lipid monolayers. J Struct Biol (2001) 0.80
The glycosylation of human myelin basic protein at threonines 95 and 98 occurs sequentially. Biochim Biophys Acta (1988) 0.79
Identification and characterization of endothelin converting activity from EAHY 926 cells: evidence for the physiologically relevant human enzyme. Arch Biochem Biophys (1994) 0.79
Mechanism of action of enalapril in experimental hypertension and acute left ventricular failure. J Hypertens Suppl (1983) 0.79
Computerized system analyzes epidemiological data. Hospitals (1976) 0.79
The interaction of basic proteins from normal and multiple sclerosis myelin with phosphatidylglycerol vesicles. FEBS Lett (1981) 0.79
An immunochemical comparison of human myelin basic protein and its modified, citrullinated form, C8. J Neuroimmunol (1992) 0.79
Control of the mitogenicity of muramyl dipeptide. Int J Immunopharmacol (1981) 0.79
The subcellular distribution of gastrin and secretin activity in the mucosa of the small intestine. Biochem J (1967) 0.79
Inhibition of prostaglandin biosynthesis by etodolac. I. Selective activities in arthritis. Agents Actions (1987) 0.78
Serological characterization of acidic (pI 5.5) and neutral (pI 7.1) forms of 17kD and 35kD interleukin-1. Lymphokine Res (1986) 0.78
Myelin lipophilin-induced demyelinating disease of the central nervous system. Neurochem Res (1980) 0.78
Studies on the mechanism of stimulation of the humoral response of murine spleen cultures by culture fluids from human monocytes. J Immunol (1975) 0.78
An ELISA assay for murine amyloid A and serum amyloid A utilizing monoclonal antibodies. J Immunol Methods (1982) 0.77
Sensitization to myelin basic protein in attacks of multiple sclerosis. A preliminary report. J Neurol Sci (1978) 0.77
Central antihypertensive effects of inhibitors of the renin-angiotensin system in rats. Am J Physiol (1976) 0.77
Nonspecific "lymphocyte activating" factors produced by macrophages. Clin Immunol Immunopathol (1979) 0.77
A monoclonal anti-type II collagen antibody with cross-reactive anti-Ig activity specific for the F(ab')2 fragment. J Immunol (1988) 0.77
A paracrystalline inclusion in Neurospora crassa. Induction by ethidium and acridine, isolation, and characterization. J Cell Biol (1971) 0.77
X-ray scattering studies of a model complex of lipid and basic protein of myelin. Biochim Biophys Acta (1984) 0.77
Transmembrane orientation of lipophilin in phosphatidylcholine vesicles. Neurochem Res (1980) 0.77
Marburg's variant of multiple sclerosis correlates with a less compact structure of myelin basic protein. Mol Cell Biol Res Commun (1999) 0.76
Relationship between angiotensin I blockade and antihypertensive properties of single doses of MK-421 and captopril in spontaneous and renal hypertensive rats. Eur J Pharmacol (1981) 0.76
Interaction of glycosylated human myelin basic protein with lipid bilayers. Biochemistry (1989) 0.76
Localization and partial characterization of a 60 kDa citrulline-containing transport form of myelin basic protein from MO3-13 cells and human white matter. J Neurosci Res (1995) 0.76
Conformational studies on 13C-enriched human and bovine myelin basic protein, in solution and incorporated into liposomes. Biochemistry (1978) 0.76
The identification of threonine-95 as the major site of glycosylation in normal human myelin basic protein. Biochem J (1984) 0.75
Functional consequences of perceived interleukin deficiencies? Analysis employing NZB x C58 recombinant inbred mice. Clin Exp Immunol (1985) 0.75
The effect of metals on the binding of 131-I-labelled acid-soluble protein to myelin in vitro. Can J Biochem (1968) 0.75
Contamination of commercial leukocyte-derived human interleukin 2 with interleukin 1. Lymphokine Res (1985) 0.75
An ELISA for PGE2 utilizing monoclonal antibody. J Immunoassay (1988) 0.75
Studies on chemically modified forms of the myelin basic protein: requirements for encephalitogenicity. FEBS Lett (1976) 0.75
A simple method for the preparation and storage of helper T cells. J Immunol Methods (1978) 0.75
Nonspecific "lymphocyte activating" factors produced by macrophages. Cell Immunol (1979) 0.75
Glycolipids as host resistance stimulators. J Med Chem (1990) 0.75
Response of CBA/N mice to human B cell activating factor. Cell Immunol (1978) 0.75
A behaviorally based logbook. J Appl Behav Anal (1977) 0.75
Myelin lipophilin-induced experimental allergic encephalomyelitis in guinea pigs. Prog Clin Biol Res (1980) 0.75
Antimyelin basic protein antibodies and cellular hypersensitivity in multiple sclerosis. Trans Am Neurol Assoc (1976) 0.75
The nurse as therapist: assertion training to rehabilitate the chronic mental patient. J Psychiatr Nurs Ment Health Serv (1975) 0.75
Comparison of the plaque-stimulating and thymocyte-stimulating activities derived from human monocytes. Ann N Y Acad Sci (1979) 0.75
The localization of the basic protein and N-2 in diseased myelin. Brain Res (1975) 0.75
Lipophilin-induced experimental allergic encephalomyelitis in guinea pigs. J Neurosci Res (1982) 0.75
Polypeptides in cerebral myelin from normal humans and patients dying with multiple sclerosis. Neurology (1968) 0.75
Immunological analysis of the amino terminal and the C8 isomer of human myelin basic protein. J Neuroimmunol (1993) 0.75
Steroidal glycolipid, L-644,257, is a potent enhancer of nonspecific host resistance. Int J Immunopharmacol (1990) 0.75
Interaction between human myelin basic protein and lipophilin. Neurochem Res (1984) 0.75
Prostaglandins in inflammatory bone pathology: mechanism and therapeutic benefit of etodolac. Agents Actions (1989) 0.75
The interaction of antibodies to two myelin proteins. Immunol Commun (1975) 0.75
Discovery and initial structure-activity relationships of trisubstituted ureas as thrombin receptor (PAR-1) antagonists. Bioorg Med Chem Lett (2001) 0.75